Francis JN - Search Results

1

Characterisation of a wild-type influenza (A/H1N1) virus strain as an experimental challenge agent in humans.

Watson JM, Francis JN, Mesens S, Faiman GA, Makin J, Patriarca P, Treanor JJ, Georges B, Bunce CJ. Watson JM, et al. Among authors: francis jn. Virol J. 2015 Feb 3;12:13. doi: 10.1186/s12985-015-0240-5. Virol J. 2015. PMID: 25645025 Free PMC article.

2

A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety.

Francis JN, Bunce CJ, Horlock C, Watson JM, Warrington SJ, Georges B, Brown CB. Francis JN, et al. Vaccine. 2015 Jan 3;33(2):396-402. doi: 10.1016/j.vaccine.2014.06.006. Epub 2014 Jun 10. Vaccine. 2015. PMID: 24928790 Free article. Clinical Trial.

3

Development of an objective gene expression panel as an alternative to self-reported symptom scores in human influenza challenge trials.

Muller J, Parizotto E, Antrobus R, Francis J, Bunce C, Stranks A, Nichols M, McClain M, Hill AVS, Ramasamy A, Gilbert SC. Muller J, et al. J Transl Med. 2017 Jun 8;15(1):134. doi: 10.1186/s12967-017-1235-3. J Transl Med. 2017. PMID: 28595644 Free PMC article. Clinical Trial.

4

Nasal IgA Provides Protection against Human Influenza Challenge in Volunteers with Low Serum Influenza Antibody Titre.

Gould VMW, Francis JN, Anderson KJ, Georges B, Cope AV, Tregoning JS. Gould VMW, et al. Among authors: francis jn. Front Microbiol. 2017 May 17;8:900. doi: 10.3389/fmicb.2017.00900. eCollection 2017. Front Microbiol. 2017. PMID: 28567036 Free PMC article.

5

Increasing cellular immunogenicity to peptide-based vaccine candidates using a fluorocarbon antigen delivery system.

Francis JN, Thaburet JF, Bonnet D, Sizer PJ, Brown CB, Georges B. Francis JN, et al. Vaccine. 2015 Feb 18;33(8):1071-6. doi: 10.1016/j.vaccine.2014.12.061. Epub 2015 Jan 6. Vaccine. 2015. PMID: 25573036

6

Multi-tissue transcriptional changes and core circadian clock disruption following intensive care.

Hollis HC, Francis JN, Anafi RC. Hollis HC, et al. Among authors: francis jn. Front Physiol. 2022 Aug 15;13:942704. doi: 10.3389/fphys.2022.942704. eCollection 2022. Front Physiol. 2022. PMID: 36045754 Free PMC article.

7

Collective market shaping by competitors and its contribution to market resilience.

Beninger S, Francis JNP. Beninger S, et al. Among authors: francis jnp. J Bus Res. 2021 Jan;122:293-303. doi: 10.1016/j.jbusres.2020.09.005. Epub 2020 Sep 16. J Bus Res. 2021. PMID: 32958968 Free PMC article.

8

Prevention and treatment of SHIVAD8 infection in rhesus macaques by a potent d-peptide HIV entry inhibitor.

Nishimura Y, Francis JN, Donau OK, Jesteadt E, Sadjadpour R, Smith AR, Seaman MS, Welch BD, Martin MA, Kay MS. Nishimura Y, et al. Among authors: francis jn. Proc Natl Acad Sci U S A. 2020 Sep 8;117(36):22436-22442. doi: 10.1073/pnas.2009700117. Epub 2020 Aug 20. Proc Natl Acad Sci U S A. 2020. PMID: 32820072 Free PMC article.

9

Chemical synthesis of Shiga toxin subunit B using a next-generation traceless "helping hand" solubilizing tag.

Fulcher JM, Petersen ME, Giesler RJ, Cruz ZS, Eckert DM, Francis JN, Kawamoto EM, Jacobsen MT, Kay MS. Fulcher JM, et al. Among authors: francis jn. Org Biomol Chem. 2019 Dec 28;17(48):10237-10244. doi: 10.1039/c9ob02012h. Epub 2019 Dec 3. Org Biomol Chem. 2019. PMID: 31793605

10

Characterization of resistance to a potent D-peptide HIV entry inhibitor.

Smith AR, Weinstock MT, Siglin AE, Whitby FG, Francis JN, Hill CP, Eckert DM, Root MJ, Kay MS. Smith AR, et al. Among authors: francis jn. Retrovirology. 2019 Oct 22;16(1):28. doi: 10.1186/s12977-019-0489-7. Retrovirology. 2019. PMID: 31640718 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

44 results

Search Page

Filters